You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
MTHFR 677 TT genotype and hyperhomocysteinaemia: an underestimated risk TANDEM for patients with stroke
  1. V Caso,
  2. M Paciaroni
  1. Stroke Unit, Ospedale Silvestrini, Perugia, Italy
  1. Correspondence to:
 V Caso
 Stroke Unit, Ospedale Silvestrini, San’ Andrea delle Fratte, 06146 Perugia, Italy;vcaso{at}hotmail.com

https://doi.org/10.1136/jnnp.2006.095505

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Synergy between hyperhomocysteinaemia and conventional risk factors for stroke

    Hyperhomocysteinaemia (hyperH(e)) is still considered to be one of the less documented risk factors for stroke.1 One of the most frequent causes of hyperH(e) is a single-nucleotide polymorphism in the gene methylenetetrahydrofolate reductase (MTHFR). The homozygotic TT genotype is found in approximately 10–12% of the population and is associated with a 25% higher homocysteine level in patients with than in those without this mutation.1

    The distribution of the MTHFR 677 TT genotype and hyperH(e) in young patients with stroke aged <45 years was compared with that in healthy controls in the paper by Pezzini et al2 (see p …

    View Full Text

    Footnotes

    • Published Online First 16 June 2006

    • Competing interests: None declared.

    Linked Articles